Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
Drug Efficacy Studies in Custom Model_ Muscular Dystrophy Mouse Model
In order to meet the diversifying needs of our clients, we often use our years of expertise conducting preclinical animal models to help our clients establish custom models that are not currently on our lineup. This process involves evaluating the potential efficacy of a model based on the available literature and then running the model…
2025.02.02
Preclinical studies for COPD research: PPE model
We would like to share with you about our Porcine pancreatic elastase (PPE)-induced pulmonary emphysema model, known as a disease model for chronic obstructive pulmonary disease (COPD). This model develops pulmonary emphysema due to elastin degradation in the lung tissue and consequent immune cell infiltration caused by elastin fragments. Here at SMC, we use a Microsprayer…
2025.02.02
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. Nonalcoholic fatty liver…
2025.02.02
New drugs for chronic kidney disease are desired
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population? Last year, the following article was published in Nature Reviews Nephrology (Soler et al., Nature Reviews Nephrology., 2021). The COVID-19 pandemic: progress in nephrology The…
2025.02.02
Clinically correlated gut dysfunction in liver disease model
We would like to share with you our presentation from the 5th Korea Digestive Disease Week (KDDW 2021) (November 18 to 20, 2021). ABS-0579| Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet In this presentation, the increased intestinal permeability or…
2025.02.02
Combination study with our proprietary NASH-HCC model
We would like to introduce the combination study using NASH model mice. Combination study in NASH These days, a lot of pharmaceutical companies are trying to conduct combination studies for NASH. Since NASH shows a variety of symptoms like steatosis, inflammation and fibrosis, pharmaceutical companies expect synergistic effect through administration of drug candidates which…
2025.02.02
SSc-ILD mouse model for simultaneous development of skin and lung fibrosis
We would like to introduce our SSc-ILD model – an improvement on our existing systemic scleroderma model – which is a more clinically relevant model of fibrosis that develops in both the skin and lungs. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues…
2025.02.02
Acute Lung Injury mouse model shows similar symptoms to COVID-19 patients
We would like to introduce the Liposaccharide-induced Acute Lung Injury model (LPS model) – an ARDS model that shows symptoms similar to that of COVID-19 patients. It has been reported that COVID-19 patients develop symptoms of acute pneumonia and lung fibrosis. Acute pneumonia presents as an initial symptom of lung injury, and progresses to…
2025.02.02
Liver Orthotopic Xenograft mouse model
We would like to introduce the Liver Orthotopic Xenograft mouse model – a cancer model that also allows the evaluation of the tumor microenvironment. The number of deaths from cancer continues to rise as medical advances extend life spans. Therefore, there is a high requirement for the development of therapeutic drugs for various cancers,…
2025.02.02
Performance of FXR agonist pharmacology studies using our NASH model
We would like to share with you about our experience evaluating farnesoid X receptor (FXR) agonists in the world’s first mouse model that induces liver cancer from nonalcoholic steatohepatitis (NASH) – the STAM™ model – developed by SMC Laboratories, Inc. The nuclear receptor FXR is activated by bile acids and involved in the regulation…
We can help you advance your research.